In support of this conclusion, BCI, a compound identified as an allosteric inhibitor of DUSP6/MKP-3, caused a rapid increase in ERK activity in patient-derived Ph+ ALL cells. The gene discussed is MAPK1; the disease is acute lymphoblastic leukemia.